New cervical cancer technologies prove cost-effective for infrequent screening
This article was originally published in Clinica
Cervical cancer technologies that are designed to increase the sensitivity of Pap testing are more cost-effective than conventional tests but only when used for infrequent screening, according to an outcomes model devised by two epidemiologists. But if they were to be used as part of a less frequent screening programme, the higher cost of an individual test might deter some women from taking part, they warn in the Journal of the American Medical Association (January 27).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.